|
1
|
Petrelli F, Cabiddu M, Ghilardi M and
Barni S: Current data of targeted therapies for the treatment of
triple-negative advanced breast cancer: Empiricism or
evidence-based? Expert Opin Investig Drugs. 18:1467–1477. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Podo F, Buydens LM, Degani H, Hilhorst R,
Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J,
Monleon D, et al: FEMME Consortium: Triple-negative breast cancer:
Present challenges and new perspectives. Mol Oncol. 4:209–229.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carey LA, Dees EC, Sawyer L, Gatti L,
Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou
CM: The triple negative paradox: Primary tumor chemosensitivity of
breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reis-Filho JS and Tutt AN: Triple negative
tumours: A critical review. Histopathology. 52:108–118. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wakeling AE, Guy SP, Woodburn JR, Ashton
SE, Curry BJ, Barker AJ and Gibson KH: ZD1839 (Iressa): An orally
active inhibitor of epidermal growth factor signaling with
potential for cancer therapy. Cancer Res. 62:5749–5754.
2002.PubMed/NCBI
|
|
6
|
Anderson NG, Ahmad T, Chan K, Dobson R and
Bundred NJ: ZD1839 (Iressa), a novel epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the
growth of EGFR-positive cancer cell lines with or without erbB2
overexpression. Int J Cancer. 94:774–782. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Baselga J, Albanell J, Ruiz A, Lluch A,
Gascón P, Guillém V, González S, Sauleda S, Marimón I, Tabernero
JM, et al: Phase II and tumor pharmacodynamic study of gefitinib in
patients with advanced breast cancer. J Clin Oncol. 23:5323–5333.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gutteridge E, Agrawal A, Nicholson R,
Cheung K Leung, Robertson J and Gee J: The effects of gefitinib in
tamoxifen-resistant and hormone-insensitive breast cancer: A phase
II study. Int J Cancer. 126:1806–1816. 2010.PubMed/NCBI
|
|
9
|
Filardo EJ, Quinn JA, Frackelton AR Jr and
Bland KI: Estrogen action via the G protein-coupled receptor,
GPR30: Stimulation of adenylyl cyclase and cAMP-mediated
attenuation of the epidermal growth factor receptor-to-MAPK
signaling axis. Mol Endocrinol. 16:70–84. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Haynes MP, Li L, Sinha D, Russell KS,
Hisamoto K, Baron R, Collinge M, Sessa WC and Bender JR: Src kinase
mediates phosphatidylinositol 3-kinase/Akt-dependent rapid
endothelial nitric-oxide synthase activation by estrogen. J Biol
Chem. 278:2118–2123. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luttrell LM, Daaka Y and Lefkowitz RJ:
Regulation of tyrosine kinase cascades by G-protein-coupled
receptors. Curr Opin Cell Biol. 11:177–183. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen ZJ, Wei W, Jiang GM, Liu H, Wei WD,
Yang X, Wu YM, Liu H, Wong CK, Du J, et al: Activation of GPER
suppresses epithelial mesenchymal transition of triple negative
breast cancer cells via NF-κB signals. Mol Oncol. 10:775–788. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ignatov A, Ignatov T, Weissenborn C,
Eggemann H, Bischoff J, Semczuk A, Roessner A, Costa SD and
Kalinski T: G-protein-coupled estrogen receptor GPR30 and tamoxifen
resistance in breast cancer. Breast Cancer Res Treat. 128:457–466.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Steiman J, Peralta EA, Louis S and Kamel
O: Biology of the estrogen receptor, GPR30, in triple negative
breast cancer. Am J Surg. 206:698–703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Girgert R, Emons G and Gründker C:
Inactivation of GPR30 reduces growth of triple-negative breast
cancer cells: Possible application in targeted therapy. Breast
Cancer Res Treat. 134:199–205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vivacqua A, Lappano R, De Marco P, Sisci
D, Aquila S, De Amicis F, Fuqua SA, Andò S and Maggiolini M: G
protein-coupled receptor 30 expression is up-regulated by EGF and
TGF alpha in estrogen receptor alpha-positive cancer cells. Mol
Endocrinol. 23:1815–1826. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nielsen TO, Hsu FD, Jensen K, Cheang M,
Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler
L, et al: Immunohistochemical and clinical characterization of the
basal-like subtype of invasive breast carcinoma. Clin Cancer Res.
10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Girgert R, Bartsch C, Hill SM, Kreienberg
R and Hanf V: Tracking the elusive antiestrogenic effect of
melatonin: A new methodological approach. Neuro Endocrinol Lett.
24:440–444. 2003.PubMed/NCBI
|
|
19
|
Stanley ER, Palmer RE and Sohn U:
Development of methods for the quantitative in vitro analysis of
androgen-dependent and autonomous Shionogi carcinoma 115 cells.
Cell. 10:35–44. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen S, Zhou D, Yang C, Okubo T, Kinoshita
Y, Yu B, Kao YC and Itoh T: Modulation of aromatase expression in
human breast tissue. J Steroid Biochem Mol Biol. 79:35–40. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
von Minckwitz G, Jonat W, Fasching P, du
Bois A, Kleeberg U, Lück HJ, Kettner E, Hilfrich J, Eiermann W,
Torode J, et al: A multicentre phase II study on gefitinib in
taxane- and anthracycline-pretreated metastatic breast cancer.
Breast Cancer Res Treat. 89:165–172. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Green MD, Francis PA, Gebski V, Harvey V,
Karapetis C, Chan A, Snyder R, Fong A, Basser R and Forbes JF:
Australian New Zealand Breast Cancer Trials Group: Gefitinib
treatment in hormone-resistant and hormone receptor-negative
advanced breast cancer. Ann Oncol. 20:1813–1817. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carey LA, Rugo HS, Marcom PK, Mayer EL,
Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A,
et al: TBCRC 001: Randomized phase II study of cetuximab in
combination with carboplatin in stage IV triple-negative breast
cancer. J Clin Oncol. 30:2615–2623. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bernsdorf M, Ingvar C, Jörgensen L, Tuxen
MK, Jakobsen EH, Saetersdal A, Kimper-Karl ML, Kroman N, Balslev E
and Ejlertsen B: Effect of adding gefitinib to neoadjuvant
chemotherapy in estrogen receptor negative early breast cancer in a
randomized phase II trial. Breast Cancer Res Treat. 126:463–470.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Girgert R, Emons G and Gründker C:
Inhibition of GPR30 by estriol prevents growth stimulation of
triple-negative breast cancer cells by 17β-estradiol. BMC Cancer.
14:9352014. View Article : Google Scholar : PubMed/NCBI
|
